Iovance picks up IL-2 Proleukin for $200M+ upfront; Estrella Biopharma to wait for SPAC deal finish
The UK-based biotech Clinigen will divest from one of its IL-2 candidates and sell it to Iovance Biotherapeutics.
In an announcement on Monday, Iovance will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
